Total Payments
$41,434
2024 Payments
$4,835
Companies
56
Transactions
1,810
Medicare Patients
4,049
Medicare Billing
$2.4M
Payment Breakdown by Category
Food & Beverage$36,598 (88.3%)
Other$4,104 (9.9%)
Education$732.21 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $36,598 | 1,779 | 88.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,104 | 3 | 9.9% |
| Education | $732.21 | 28 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $7,006 | 321 | $0 (2024) |
| Organogenesis Inc. | $4,500 | 19 | $0 (2023) |
| ViiV Healthcare Company | $4,490 | 214 | $0 (2024) |
| ABBVIE INC. | $2,900 | 124 | $0 (2024) |
| CIPLA USA INC. | $2,364 | 13 | $0 (2021) |
| Melinta Therapeutics, LLC | $2,310 | 130 | $0 (2024) |
| Merck Sharp & Dohme LLC | $2,309 | 161 | $0 (2024) |
| Insmed, Inc. | $2,194 | 89 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $1,696 | 71 | $0 (2023) |
| Smith+Nephew, Inc. | $1,390 | 132 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,835 | 194 | Gilead Sciences, Inc. ($1,270) |
| 2023 | $5,198 | 240 | Gilead Sciences, Inc. ($1,353) |
| 2022 | $5,258 | 245 | ABBVIE INC. ($788.56) |
| 2021 | $7,160 | 260 | CIPLA USA INC. ($2,364) |
| 2020 | $3,299 | 166 | Merck Sharp & Dohme Corporation ($455.69) |
| 2019 | $4,075 | 227 | Gilead Sciences, Inc. ($926.83) |
| 2018 | $8,289 | 266 | Organogenesis Inc. ($4,000) |
| 2017 | $3,320 | 212 | Gilead Sciences Inc ($653.48) |
All Payment Transactions
1,810 individual payment records from CMS Open Payments — Page 1 of 73
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.49 | General |
| 12/17/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: HIV | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.98 | General |
| 12/12/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: ANTIBIOTICS | ||||||
| 12/11/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $5.42 | General |
| Category: HIV | ||||||
| 12/04/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $5.60 | General |
| Category: ANTIBIOTICS | ||||||
| 12/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.81 | General |
| 11/25/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.74 | General |
| 11/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.36 | General |
| 11/13/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $84.19 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.16 | General |
| 11/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $5.40 | General |
| Category: HIV | ||||||
| 11/12/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ANTIBIOTICS | ||||||
| 11/12/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/11/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/09/2024 | Smith+Nephew, Inc. | GRAFIX PL (Medical Supply) | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: Other Advanced Wound Management | ||||||
| 11/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: HIV | ||||||
| 11/06/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $109.21 | General |
| Category: ANTIFUNGALS | ||||||
| 11/05/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: HIV | ||||||
| 11/05/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: HIV | ||||||
| 11/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.15 | General |
| 11/04/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: ANTIBIOTICS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 850 | 524,392 | $1.8M | $540,204 |
| 2022 | 23 | 878 | 314,172 | $1.6M | $505,712 |
| 2021 | 29 | 1,148 | 609,890 | $2.9M | $769,893 |
| 2020 | 31 | 1,173 | 437,810 | $2.8M | $603,617 |
Total Patients
4,049
Total Services
1,886,264
Medicare Billing
$2.4M
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 40 | 19,200 | $691,200 | $225,933 | 32.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 120 | 2,552 | $336,864 | $121,710 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 141 | 737 | $206,360 | $69,416 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 218 | $84,366 | $28,421 | 33.7% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 48 | 486,103 | $97,221 | $18,977 | 19.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 12 | 88 | $27,720 | $14,353 | 51.8% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 30 | 856 | $128,400 | $9,093 | 7.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 406 | $26,390 | $8,848 | 33.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $27,285 | $8,413 | 30.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 88 | $23,760 | $6,380 | 26.9% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 24 | 338 | $13,182 | $5,079 | 38.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 94 | $17,672 | $4,704 | 26.6% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 13 | 66 | $8,250 | $3,745 | 45.4% |
| J2185 | Injection, meropenem, 100 mg | Office | 2023 | 39 | 8,698 | $27,178 | $3,700 | 13.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 162 | $6,804 | $2,499 | 36.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 26 | 26 | $4,160 | $1,924 | 46.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 13 | 152 | $6,688 | $1,754 | 26.2% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 42 | 3,891 | $11,673 | $1,531 | 13.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $6,825 | $1,489 | 21.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 28 | 28 | $1,572 | $872.19 | 55.5% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 12 | 589 | $2,945 | $583.60 | 19.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 11 | 25 | $1,450 | $440.00 | 30.3% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 11 | 11 | $583.00 | $342.31 | 58.7% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 35 | 16,610 | $597,960 | $199,102 | 33.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 111 | 2,437 | $321,622 | $125,637 | 39.1% |
About Dr. Leonardo Palau, MD
Dr. Leonardo Palau, MD is a Infectious Disease healthcare provider based in The Woodlands, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982701496.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leonardo Palau, MD has received a total of $41,434 in payments from pharmaceutical and medical device companies, with $4,835 received in 2024. These payments were reported across 1,810 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($36,598).
As a Medicare-enrolled provider, Palau has provided services to 4,049 Medicare beneficiaries, totaling 1,886,264 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location The Woodlands, TX
- Active Since 09/19/2006
- Last Updated 10/06/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1982701496
Products in Payments
- Nushield (Medical Supply) $4,000
- ZEMDRI (PLAZOMICIN) (Drug) $2,364
- DALVANCE (Drug) $2,149
- Arikayce (Drug) $2,080
- DOVATO (Drug) $1,924
- VIBATIV (Drug) $1,825
- NUZYRA (Drug) $1,696
- CABENUVA (Biological) $1,155
- Baxdela (Drug) $1,107
- ZERBAXA (Drug) $1,076
- TEFLARO (Drug) $1,019
- Fetroja (Drug) $710.52
- AVYCAZ (Drug) $663.92
- Cresemba (Drug) $657.66
- Biktarvy (Drug) $566.48
- JULUCA (Drug) $551.12
- XERAVA (Drug) $543.53
- APRETUDE (Biological) $513.49
- DIFICID (Drug) $504.57
- Kimyrsa (Drug) $455.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in The Woodlands
Vipul Desai, Md, MD
Infectious Disease — Payments: $126,050
Infectious Disease $126,050
Dr. Timothy Chen, D.o, D.O
Infectious Disease — Payments: $8,258
Infectious Disease $8,258
Solomon Ghide, Md, MD
Infectious Disease — Payments: $236.60
Infectious Disease $236.60
Chi Hiong Go, Md, MD
Infectious Disease — Payments: $97.72
Infectious Disease $97.72
Sawyer Ricker, Md, MD
Infectious Disease
Infectious Disease